Cardiff Oncology Inc (CRDF)vsInsmed Inc (INSM)
CRDF
Cardiff Oncology Inc
$1.73
-2.81%
HEALTHCARE · Cap: $123.06M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 102164% more annual revenue ($606.42M vs $593,000). CRDF leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
CRDF
Avoid31
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 60.9% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CRDF
The strongest argument for CRDF centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 60.9% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CRDF
The primary concerns for CRDF are EPS Growth, Market Cap, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CRDF profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.
CRDF carries more volatility with a beta of 1.37 — expect wider price swings.
CRDF is growing revenue faster at 60.9% — sustainability is the question.
CRDF generates stronger free cash flow (-6M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cardiff Oncology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?